IOCB Tech, a leading technology transfer office in the Czech Republic, proudly attended BioJapan 2024, the largest and most influential biotechnology partnering event in Asia. Held at the Pacifico Yokohama Convention Center, this prestigious event brought together global leaders in biotechnology, regenerative medicine, and digital health, providing an ideal platform for collaboration between industry, academia, and government.
BioJapan 2024 attracted over 20,000 participants from 35 countries, including top biotech companies, research institutions, and policymakers. IOCB Tech participated in the event together with other companies such as Bioinova, IQS nano a GCP-Service and the participation of Czech companies was significantly supported by the CzechInvest agency.
„Czech companies have a rich history of innovation in biotechnology and bioindustries, and they continue to offer cutting-edge technologies, particularly through smaller startups. The sector is growing rapidly, both here in Japan and globally, and Czech businesses are well-positioned to contribute to traditional areas and emerging fields. Recent legislative and certification changes have opened up new opportunities for service companies and CROs, making the environment for partnerships even more dynamic,“ said Jakub Hajek, Director of Japanese Operations at CzechInvest.
The event is renowned for its comprehensive partnering program, which enables highly targeted business meetings to facilitate potential partnerships, technology out-licensing, and collaborative research opportunities. With its focus on the latest advancements in biopharmaceuticals, stem cell research, AI-driven drug discovery, and the industrialization of regenerative medicine, BioJapan serves as a critical forum for driving innovation across the life sciences sector.
IOCB Tech’s participation in this year’s event underscores the organization's commitment to bridging scientific discoveries with practical applications. As a key representative of the Czech Republic, IOCB Tech contributed to fostering international collaboration and innovation. The event provided the IOCB Tech team with invaluable opportunities to engage in discussions around emerging biotech trends and to explore new business partnerships that will enhance the commercialization of cutting-edge scientific research from the Czech Republic.
„The Japanese market is the world's top three in the field of biotechnology and pharmaceuticals. participation in BioJapan is therefore an important opportunity for us to present our projects, possibilities and establish or deepen contacts with important players in the field, said Martin Fusek, CEO of IOCB Tech.
At the conference, IOCB Tech mainly presented its projects focused on the treatment of epilepsy or Parkinson's disease.
With a strong emphasis on international partnerships and the application of cutting-edge research to real-world challenges, IOCB Tech’s presence at BioJapan further solidifies its role as a pivotal player in the global biotechnology ecosystem. The connections forged at this event are expected to open new avenues for collaboration and investment, particularly in the fields of next-generation biopharmaceuticals and AI-driven health technologies.